https://www.selleckchem.com/pr....oducts/baxdrostat.ht
(AL) has been demonstrated in a series of studies to be a potential candidate for the treatment of cholangiocarcinoma. The aim of the current study was to evaluate the safety and pharmacokinetics of the capsule formulation of the standardized AL extract in healthy Thai participants. Forty-eight healthy Thai participants who fulfilled the inclusion and had none of the exclusion criteria were allocated to two study groups. The participants were randomized to receive a single oral dose of 1,000mg of AL or placebo (204 participants). The
Synes godt om
Kommentar
Del
